SERUM BIOMARKER FOR BREAST CANCER

乳腺癌血清生物标志物

• 批准号: 15591329
• 负责人: MIYAZAWA Yukimasa
• 金额: $ 2.11万
• 依托单位: Chiba University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2003
• 资助国家: 日本
• 起止时间: 2003 至 2004
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-15591329/
• 关键词: Breast Cancer; Serum Marker; SEREX; SEREX; 血清抗体; ELISAキット; 早期癌

In breast cancer patients, genetic analysis of cancer cells has been reported as an important tool to evaluate malignant potential of cancer cells. However, since protein analyses require tumor specimen and complicated techniques, a simpler and less invasive method for evaluating gene expression level is necessary for clinical application. Recently, gene & protein expression level in patients with various cancers has been made possible by measuring serum concentration with enzyme-linked immunosorbent assay(ELISA) have been reported to be raised in various cancer patients and was the prognostic factor closely associated with advanced tumor stage. We, therefore, analyzed serum markers in breast cancer patients prior to treatment to determine the clinicopathological significance of serum bio-markers.

据报道，在乳腺癌患者中，癌细胞的遗传分析是评估癌细胞恶性潜力的重要工具。然而，由于蛋白质分析需要肿瘤标本和复杂的技术，因此临床应用需要一种更简单、侵入性较小的评估基因表达水平的方法。最近，通过酶联免疫吸附试验（ELISA）测量血清浓度，使得各种癌症患者的基因和蛋白质表达水平成为可能，据报道，在各种癌症患者中基因和蛋白质表达水平升高，并且是与晚期肿瘤分期密切相关的预后因素。因此，我们在治疗前分析了乳腺癌患者的血清标志物，以确定血清生物标志物的临床病理学意义。

项目成果

Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer.

• DOI: 10.3892/or.10.2.411
• 发表时间: 2003-03
• 期刊: Oncology reports
• 影响因子: 4.2
• 作者: H. Shimada;Y. Nabeya;S. Okazumi;H. Matsubara;K. Kadomatsu;T. Muramatsu;S. Ikematsu;S. Sakuma

Serological identification of tumor antigens of esophageal squamous cell carcinoma.

• DOI: 10.3892/ijo.26.1.77
• 发表时间: 2005
• 期刊: International journal of oncology
• 影响因子: 5.2
• 作者: H. Shimada;K. Nakashima;T. Ochiai;Y. Nabeya;M. Takiguchi;F. Nomura;T. Hiwasa